Chronic obstructive pulmonary disease (COPD) or also known as chronic obstructive respiratory disease is a progressive condition wherein the airways become swollen, inflamed, and clogged due to the buildup of mucus. This mucus becomes the first line of defense against any irritant which leads to difficulty in breathing, coughing, chest pain, wheezing, and shortness of breath. With time, this mucous thickens and makes it difficult for the air to pass through.
Increasing incidence of respiratory diseases is expected to drive growth of the global pulmonary drugs market. According to the Centers for Disease Control Prevention (CDC), over 25 million U.S. citizens have asthma. According to the same source, in 2017, around 1 in children had asthma. Moreover, according to the World Health Organization (WHO), in 2016, around 251 million cases of chronic pulmonary obstructive disease (COPD) were reported globally. Such a massive increase in respiratory diseases has increased the demand for pulmonary drugs worldwide. Pulmonary drug delivery offers numerous advantages due to the large internal surface area of the lung. Hence, such factors are expected to drive growth of the global pulmonary drugs market. Furthermore, growing emphasis on the development of smart or digital inhalers is expected to propel the global pulmonary drugs market growth in the near future.
Key competitors involved in the global pulmonary drugs market are AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sumitomo Dainippon Pharma Co., Ltd., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, Pfizer Inc., Grifols, S.A., and Merck & Co., Inc.
For instance, in May 2020, AstraZeneca partnered with Propeller Health to add smart features to its Symbicort inhaler for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
No comments:
Post a Comment